BCOP Updates 2023: Updates in the treatment of Relapsed/Refractory DLBCL

Type: IndividualFormat: On-demand

Treatment for diffuse large B-cell lymphoma (DLBCL) is generally well-defined in the first-line setting, with R-CHOP being the standard of care for all but the more aggressive variants of this disease. In the relapsed/refractory (r/r) setting, however, second-line treatment historically branches between those eligible to proceed to high dose chemotherapy with autologous stem cell rescue and those not deemed not candidates for transplant. In recent years, the landscape of r/r DLBCL treatment has begun to change significantly, with chimeric antigen receptor T-cell (CAR-T) therapy, bispecific T-cell engagers (BiTE) and other targeted agents providing novel options with similar or improved tolerability. However, these options are costly and have operational barriers that make usage difficult to implement. With multiple new treatment options challenging historical standards of care, it is essential for the oncology pharmacist to possess a working knowledge of new agents and the evidence at the foundation of their FDA approvals. This session will review the most updated guidelines; landmark literature on recently-approved agents; and evaluate their potential places in therapy.

Get It Now!

System Requirements

All online, interactive modules require a computer and a reliable internet connection.

If you have questions about these modules, please contact HOPA Education at education@hoparx.org.

Accreditation Statement

The Hematology/Oncology Pharmacy Association (HOPA) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. An ACPE statement of credit will be issued only upon completion of the pre/post- assessment and a post-activity evaluation form. ACPE credit must be claimed by July 19, 2024.

The Hematology/Oncology Pharmacy Association (HOPA) is accredited by the Board of Pharmacy Specialties (BPS) as a provider of Board Certified Oncology Pharmacist (BCOP) credit. A BCOP statement of credit will be issued only upon completion of a post- activity evaluation form, and post-test, a passing grade of 75% or greater is achieved. BCOP credit must be claimed by July 19, 2024 .

Disclosure of Conflicts of Interest

The Hematology/Oncology Pharmacy Association (HOPA) assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CE activities. All relevant conflicts of interest that are identified are thoroughly vetted by HOPA for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. HOPA is committed to providing its learners with high-quality CE activities and related materials that promote improvements of quality in healthcare and not a specific proprietary business interest of a commercial interest.

Reported Areas of Conflict

The Hematology/Oncology Pharmacy Association does not view the existence of relationships as an implication of bias or that the value of the material is decreased. The content of the activity was planned to be balanced, objective, and scientifically rigorous. Occasionally, authors may express opinions that represent their own viewpoint. Conclusions drawn by participants should be derived from objective analysis of scientific data. All faculty have indicated that they have not referenced unlabeled/unapproved uses of drugs and devices.

Get It Now!